Plain-English translation of NCT06657768 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Alzheimer Disease research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it is safe and how the body handles it. The study will involve either a single dose or multiple doses of the medication given through an IV (a needle in your vein), and researchers will take blood samples to measure how much of the medication enters your bloodstream and how your body processes it.
Right now there are limited treatment options for early Alzheimer's disease, and researchers are working to find new medications that might help slow memory loss. This early-stage trial is designed to make sure this new treatment is safe before testing whether it actually helps people with memory problems.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you qualify for Part A (healthy volunteers), you will receive a single IV dose of the medication or placebo and be monitored for safety over about 29 weeks total. If you qualify for Part B (people with early Alzheimer's), you will receive multiple IV doses over time and participate for about 61 weeks, with frequent visits for blood work, memory testing, and brain imaging to track how the medication affects you and your disease.
AI-generated summary from trial data ยท Jun 19, 2026 ยท Not medical advice
United States